Clinical Trial Update: Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial evaluating cetuximab and pembrolizumab in metastatic or unresectable colorectal cancer has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Recurrent Colorectal Carcinoma, Stage IVA Colorectal Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-12-03